Mural Oncology Shares Data From ARTISTRY-3 Trial Designed To Evaluate Effects Of Less Frequent Intravenous Dosing Of Nemvaleukin Alfa In Advance Of ASCO Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
Mural Oncology shared data from the ARTISTRY-3 trial, which evaluated the effects of less frequent intravenous dosing of Nemvaleukin Alfa. The trial demonstrated pharmacodynamic proof of mechanism and showed that Nemvaleukin was generally well-tolerated at all doses tested.
May 23, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mural Oncology's ARTISTRY-3 trial results for Nemvaleukin Alfa showed pharmacodynamic proof of mechanism and good tolerance at all doses, which could positively impact the stock price.
The positive results from the ARTISTRY-3 trial, demonstrating both pharmacodynamic proof of mechanism and good tolerance at all doses, are likely to boost investor confidence in Mural Oncology's product pipeline. This could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100